#United States #medical technology #Englewood #Zynex #Non-Invasive Devices

Zynex Reports Second Quarter 2025 Financial Results

Zynex, Inc. (NASDAQ: ZYXI), a pioneer in non-invasive medical devices, has announced its financial results for the second quarter of 2025. This report highlights the significant changes and challenges faced by the company during this period, as reflected in their operational metrics and strategic decisions made to bolster future growth.

Leadership Changes: A New Direction for Zynex

In a pivotal move, Zynex appointed Steven Dyson as the new CEO. Dyson brings with him over 25 years of expertise in the medical technology field, having previously held significant roles at Apax, a prominent global private equity firm. His experience equips him to guide Zynex through a transformative phase aimed at optimizing the company’s payer mix and setting the stage for renewed growth. According to Zynex's Founder and CEO Thomas Sandgaard, Dyson's leadership will be crucial as the company navigates current market challenges.

Historic Milestones in Medical Technology

Zynex also made a landmark submission for its NiCO laser pulse oximeter to the FDA. This advancement marks a significant evolution in pulse oximetry—critical for patient monitoring and care. With a focus on improving patient outcomes, Zynex is committed to innovation as part of its core strategy.

Financial Overview: Challenges and Their Impact

In the second quarter of 2025, Zynex reported net revenues of $22.3 million, a notable decline from $49.9 million reported in the same quarter last year. This dip in revenue was primarily attributed to the Tricare payment suspension and ongoing adjustments in shipment and billing processes designed to enhance patient experiences. These factors combined with a restructuring and a smaller sales force have necessitated strategic realignments within the company.

The gross profit for this quarter was $15.2 million, equating to a gross margin of 68%, compared to 80% in Q2 2024. The reduction in profit margins can be linked to a decrease in revenue and continued resource allocation towards benefitting new and existing Tricare patients, which generates higher operational costs without immediate revenue.

Sales and marketing expenses saw a remarkable 45% decrease, dropping from $23.2 million last year to $12.8 million. This reduction was primarily due to a decreased workforce, reflecting Zynex’s commitment to streamline operations.

General and administrative expenses also declined from $14.5 million to $12.7 million, illustrating continual efforts to manage costs effectively. However, the net loss for the quarter was significant, amounting to $20 million or $0.66 per share, contrasting sharply with a net income of $1.2 million the previous year.

Efforts Toward Recovery and Growth

Despite the challenges, Zynex remains focused on positive cash flow recovery. The company’s cash collections for the quarter totaled $26.1 million, with $17.5 million available in cash and cash equivalents as of June 30, 2025. Management is confident that operational efficiency improvements will result in projected annual savings of approximately $40 million, effective in Q3 and Q4.

Looking ahead, the forecast for Q3 2025 introduces a level of uncertainty, particularly with leadership transitions that have led to the suspension of revenue and profitability guidance. Dyson will spend time assessing the company’s forecasting procedures, with updates to be expected in forthcoming quarters.

Conclusion

Zynex is strategically positioning itself to return to a growth trajectory amidst an evolving healthcare landscape. By focusing on innovative products and operational efficiency, the company hopes to meet the growing demand for its non-invasive medical devices, while maintaining a commitment to patient safety and care without the potential side effects linked to traditional opioid treatments. This adaptability and commitment to improvement will be crucial as Zynex navigates the path forward in the competitive medical device market.